- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01221766
Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease
March 27, 2015 updated by: Jennifer Huang, MD, Dana-Farber Cancer Institute
The Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease
This research study will help us learn more about how chronic graft-versus-host disease affects the skin, hair and nails.
We are interested in knowing if hair and nail problems predict worse disease.
This information may help us treat patients like you in the future.
Study Overview
Status
Completed
Detailed Description
- At the initial visit, participants will have a complete examination of their skin, hair and nails. We will also test muscle strength and movement by moving the participant's arms, legs and neck. Photographs will be taken of the skin, hair and nails of they are abnormal. Blood tests will be done to check the liver and blood cell count. The participant and their legal guardian will answer questions about how the participant feels and about their health.
- Participants will then be scheduled for follow up visits at 3 months, 6 months, and 12 months. At each subsequent visit the following will be done: A complete examination of the skin, hair and nails; a test of muscle strength; photographs will be repeated; blood tests to check liver and blood cell counts; and questions about how the participant feels and about their health.
Study Type
Observational
Enrollment (Actual)
12
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02115
- Children's Hospital Boston
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The research subject population is children who have received hematopoietic stem cell transplant and developed chronic graft-versus-host disease.
All children seen at the pediatric GVHD clinic at the Dana-Farber Cancer Institute will be recruited.
Description
Inclusion Criteria:
- Received hematopoietic stem cell transplant
- Meet the diagnostic criteria for cutaneous cGVHD
Exclusion Criteria:
- Previous HSCT (other then the current HSCT)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adnexal involvement
Time Frame: 1 year
|
To determine if adnexal involvement predicts worse severity and/or prognosis in chronic GVHD.
This will be measured by administration of systemic therapy other than steroids.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2010
Primary Completion (ACTUAL)
April 1, 2013
Study Completion (ACTUAL)
October 1, 2014
Study Registration Dates
First Submitted
October 14, 2010
First Submitted That Met QC Criteria
October 14, 2010
First Posted (ESTIMATE)
October 15, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
March 31, 2015
Last Update Submitted That Met QC Criteria
March 27, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10-163
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Graft vs Host Disease
-
Novartis PharmaceuticalsRecruitingChronic Graft vs. Host Disease | Graft vs. Host Disease | Corticosteroid-refractory Chronic Graft vs. Host DiseaseChina
-
Rambam Health Care CampusWithdrawnFecal Microbiota Transplantation in Graft vs. Host DiseaseIsrael
-
Dana-Farber Cancer InstituteBayer; Genzyme, a Sanofi CompanyCompleted
-
Washington University School of MedicineCompletedGraft Vs Host Disease | Graft-versus-host-diseaseUnited States
-
Novartis PharmaceuticalsCompletedCorticosteroid Refractory Acute Graft vs Host DiseaseGermany, Japan, Saudi Arabia, Turkey, United Kingdom, Spain, Canada, Italy, Australia, Austria, France, Korea, Republic of, Hong Kong, Israel, Netherlands, Russian Federation, Denmark, Greece, Taiwan, Norway, Czechia, Bulgaria
-
Rabin Medical CenterUnknownGraft Vs Host DiseaseIsrael
-
Shenzhen University General HospitalRecruitingGraft Vs Host DiseaseChina
-
National Cancer Institute (NCI)TerminatedGraft vs Host Disease | Graft-Versus-Host Disease | Chronic Graft vs. Host DiseaseUnited States
-
Hadassah Medical OrganizationBioIncept LLCUnknown
-
HomeoTherapy Co., LtdCompletedGraft-vs-Host DiseaseKorea, Republic of